Bolt Biotherapeutics, Inc. (BOLT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Bolt Biotherapeutics, Inc. (BOLT) closed at USD 4.24 on 2026-10-15, a change of -27.6 % over the past year, with a market capitalization of USD 7.71M.

Bolt Biotherapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bolt Biotherapeutics, Inc. key figures

Previous close

USD 4.24 (2026-10-15)

1-year change

-27.6 %

Market cap

USD 7.71M

Enterprise value

USD 11.73M

P/E ratio (trailing)

-0.24

P/E ratio (forward)

-0.20

EPS (trailing)

-16.51

EPS (forward)

-20.19

PEG ratio

n/a

Price to book

0.61

Revenue growth

-99.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.72

Employees

23

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bolt Biotherapeutics, Inc. and compare it with other stocks.